

13-02-09

Medigard's \$1.25m push for funds

by Jake Dew

A GOLD Coast company is banking on its shareholders to help raise funds so it can market its retractable syringe in the US.

Medigard, the Main Beach company that last year received an Australian patent for its auto-retractable syringe, hopes to raise \$1.25 million under the share-purchase plan.

In a letter sent to shareholders, Medigard chairman Donald Channer said funds raised through the plan would assist the company to market to potential strategic partners and to finalise regulatory submissions in the US of its most important product, the safety retractable syringe.

Funds also would help develop a range to include 1ml, 5ml and 10ml syringes, design and develop a range of pre-filled syringes, auto-inject syringes and intravenous valves and fulfil other capital requirements.

"Unfortunately the company has not been immune from the devaluation of investments held in supposedly reputable and well-ranked securities," said Mr Channer in the letter.

"This has diminished immediately available funds needed to complete our objectives."

Existing shareholders get the opportunity to purchase up to \$5000 worth of ordinary stock at a discounted rate free of all brokerage, commissions and stamp duty.

They will be offered at a price equal to the lower of either 6c per share or a 15 per cent discount of the company's current share price.

Medigard shares last night closed at 7c, down .5c.